Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q3 2024 ▲▼ | Q4 2024 ▲▼ | Change ▲▼ | Q3 2024 ▲▼ | Q4 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| GeneDx Holdings Corp.CL A(WGS) | 1,045,768 | 1,023,468 | -22,300 | $44.38M | $78.66M | 52.82% | +$34.28M |
| Biohaven Ltd.(BHVN) | 705,250 | 851,770 | +146,520 | $35.24M | $31.81M | 21.36% | -$3.43M |
| Ardelyx Inc | 1,369,200 | 2,089,431 | +720,231 | $9.43M | $10.59M | 7.11% | +$1.16M |
| Springworks Therapeutics Inc | 34,200 | 254,773 | +220,573 | $1.10M | $9.20M | 6.18% | +$8.11M |
| QuidelOrtho Corporation(QDEL) | 118,291 | 118,291 | 0 | $5.39M | $5.27M | 3.54% | -$124.2K |
| BioCryst Pharmaceuticals, Inc.(BCRX) | 535,558 | 535,558 | 0 | $4.07M | $4.03M | 2.70% | -$42.8K |
| Forian Inc COM | 1,356,107 | 1,366,107 | +10,000 | $2.93M | $2.81M | 1.89% | -$115.0K |
| Palantir Technologies Inc.CL A(PLTR) | 27,500 | 28,500 | +1,000 | $1.02M | $2.16M | 1.45% | +$1.13M |
| CAVA Group, Inc.(CAVA) | 18,600 | 18,600 | 0 | $2.30M | $2.10M | 1.41% | -$205.5K |
| Phathom Pharmaceuticals, Inc.(PHAT) | 749,487 | 145,064 | -604,423 | $13.55M | $1.18M | 0.79% | -$12.37M |
| Pacific Biosciences of California, Inc.(PACB) | 727,877 | 279,638 | -448,239 | $1.24M | $511.7K | 0.34% | -$725.7K |
| Biogen Inc.(BIIB) | 2,412 | 2,412 | 0 | $467.5K | $368.8K | 0.25% | -$98.7K |
| EyePoint, Inc.(EYPT) | 32,500 | 32,500 | 0 | $259.7K | $242.1K | 0.16% | -$17.6K |
| Biodesix, Inc.(BDSX) | 28,916 | 0 | -28,916 | $51.5K | $0 | — | -$51.5K |
| Myriad Genetics, Inc.(MYGN) | 134,500 | 0 | -134,500 | $3.68M | $0 | — | -$3.68M |